Humacyte, Inc. (HUMA)

Humacyte, Inc. is a commercial-stage biotechnology platform company developing off-the-shelf, universally implantable, bioengineered human tissues at commercial scale. Its first FDA-approved product, Symvess, received full FDA approval on December 19, 2024, and the U.S. commercial launch began in the first quarter of 2025. The company aims to overcome limitations in existing standards of care for tissue repair, reconstruction and replacement. Humacyte became public through a merger with Alpha Healthcare Acquisition Corp. that closed on August 26, 2021, with Humacyte Global, Inc. (formerly Legacy Humacyte) as a wholly owned subsidiary.

The company's initial products are acellular tissue engineered vessels (ATEVs). Symvess is approved for adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and autologous vein graft is not feasible. Humacyte is building a "cabinet" of ATEVs in varying diameters and lengths, targeting vascular trauma, arteriovenous (AV) access for hemodialysis, and peripheral artery disease (PAD). It is also developing the ATEV for coronary artery bypass grafting and pediatric heart surgery. Longer-term programs include a BioVascular Pancreas for pancreatic islet cell transplantation in Type 1 diabetes, plus urinary conduit, trachea, esophagus and other cell delivery applications. A Phase 3 trial (V007) of the 6 millimeter ATEV in AV access for hemodialysis met its co-primary endpoints, and a second Phase 3 trial (V012) in women is ongoing. Humacyte plans to submit a supplemental BLA in the second half of 2026, depending on interim V012 results. It has completed Phase 2 trials in PAD. The ATEV has received Fast Track and multiple Regenerative Medicine Advanced Therapy designations, and a Department of Defense priority designation. As of December 31, 2025, approximately 636 patients had received ATEVs in clinical trials, along with additional patients after the commercial launch.

The company serves surgeons and patients in hospitals, trauma centers and outpatient surgical settings, where ATEVs can be refrigerated and used immediately. Civilian and military vascular trauma is the lead market. Humacyte estimates roughly 26,000 U.S. patients per year are eligible for the ATEV in trauma. Existing options, autologous veins and synthetic grafts, have drawbacks such as harvest-site morbidity, delays in restoring blood flow, insufficient vein availability, and infection risk in contaminated wounds. Surgeons have requested the ATEV through expanded access cases, and Ukrainian surgeons requested it for a humanitarian program. Humacyte intends to shape its commercial and distribution strategy by indication and to pursue collaborations with partners where they offer strategic opportunities.

Humacyte manufactures in its own 83,000 square foot bioprocessing facility. Donor-derived human aortic vascular cells are expanded and seeded onto a biodegradable polymer mesh in single-use bioreactor bags. The cells build extracellular matrix, and the vessel is then decellularized. The process is functionally closed, highly automated and modular. Each LUNA200 system produces up to 200 ATEVs of 42cm per batch. Eight systems are operational, and the facility can expand to over 40. The FDA inspected the facility in April 2024 during its BLA review. The technology is protected by 15 patent families, some licensed and some developed internally. The company's CEO and founder is Laura Niklason, M.D., Ph.D.